Varsha Iyer

1.5k total citations
17 papers, 280 citations indexed

About

Varsha Iyer is a scholar working on Molecular Biology, Hematology and Physiology. According to data from OpenAlex, Varsha Iyer has authored 17 papers receiving a total of 280 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Hematology and 6 papers in Physiology. Recurrent topics in Varsha Iyer's work include Erythrocyte Function and Pathophysiology (6 papers), Hemoglobinopathies and Related Disorders (4 papers) and Hemoglobin structure and function (3 papers). Varsha Iyer is often cited by papers focused on Erythrocyte Function and Pathophysiology (6 papers), Hemoglobinopathies and Related Disorders (4 papers) and Hemoglobin structure and function (3 papers). Varsha Iyer collaborates with scholars based in United States, Spain and Singapore. Varsha Iyer's co-authors include Sujata M. Bhavnani, Paul G. Ambrose, Scott A. Van Wart, Daniel K. Reynolds, Donald N. Buell, Laura Kovanda, Jeffrey Hammel, David R. Andes, Brian J. Knoll and Brian M. Cox and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Neurochemistry.

In The Last Decade

Varsha Iyer

16 papers receiving 278 citations

Peers

Countries citing papers authored by Varsha Iyer

Since Specialization

Citations

This map shows the geographic impact of Varsha Iyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Varsha Iyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Varsha Iyer more than expected).

Fields of papers citing papers by Varsha Iyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Varsha Iyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Varsha Iyer. The network helps show where Varsha Iyer may publish in the future.

Co-authorship network of co-authors of Varsha Iyer

This figure shows the co-authorship network connecting the top 25 collaborators of Varsha Iyer. A scholar is included among the top collaborators of Varsha Iyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Varsha Iyer. Varsha Iyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors. 2025 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Michael Cecchini, Moh’d Khushman, (unknown), Jordi Rodón, Shivaani Kummar, Rona Yaeger, Sunil Sharma, Amber L. Wells, (unknown), (unknown), Ziyang Yu, Varsha Iyer, (unknown), Keith Orford, Samuel J. Klempner	0
2	A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors. 2024 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Jordi Rodón, Moh’d Khushman, Sunil Sharma, (unknown), Michael Cecchini, Shivaani Kummar, Minjung Choi, (unknown), (unknown), Ziyang Yu, Varsha Iyer, (unknown), Keith Orford, Samuel J. Klempner	6
3	Relative Bioavailability Studies With Mitapivat: Formulation and Food Effect Assessments in Healthy Subjects 2024 ·Clinical Pharmacology in Drug Development ·Varsha Iyer, Karen A. Sullivan, (unknown), Peter Hawkins	1
4	An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivat 2023 ·Clinical and Translational Science ·Chandra Prakash, (unknown), (unknown), Hua Yang, Varsha Iyer	4
5	Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers 2022 ·Blood ·(unknown), (unknown), Varsha Iyer, (unknown), (unknown), (unknown), (unknown), Michael U. Callaghan	6
6	A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease 2022 ·Blood ·Julia Xu, Anna Conrey, Ingrid Frey, (unknown), Laurel A. Menapace, Laxminath Tumburu, (unknown), (unknown), Quan Li, (unknown), Emily B. Dunkelberger, Varsha Iyer, (unknown), Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William A. Eaton, Swee Lay Thein	47
7	Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study 2021 ·Blood ·Julia Xu, Anna Conrey, Ingrid Frey, (unknown), Laurel A. Menapace, Laxminath Tumburu, (unknown), Quan Li, (unknown), Varsha Iyer, (unknown), Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William A. Eaton, Swee Lay Thein	8
8	Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers 2021 ·Blood ·Varsha Iyer, (unknown), Sébastien Ronseaux, (unknown), (unknown), (unknown), Michael U. Callaghan	2
9	Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease 2020 ·Blood ·Julia Xu, Anna Conrey, Ingrid Frey, James Nichols, Laurel A. Menapace, Laxminath Tumburu, (unknown), Quan Li, Emily B. Dunkelberger, Eric R. Henry, Troy Cellmer, Varsha Iyer, (unknown), Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William A. Eaton, Swee Lay Thein	7
10	Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion 2019 ·Molecular Cancer Therapeutics ·Rebecca S. Heist, Mrinal M. Gounder, Sophie Postel‐Vinay, (unknown), Elena Garralda, T. Khanh, Geoffrey I. Shapiro, Patricia Martín-Romano, Gerburg M. Wulf, Michael K. Cooper, Caroline Almon, Salah Nabhan, Varsha Iyer, Yanwei Zhang, Kevin M. Marks, Elia Aguado-Fraile, Frank G. Basile, Keith T. Flaherty, Howard A. Burris	5
11	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor 2018 ·Investigational New Drugs ·James J. Harding, Todd M. Bauer, Daniel Shao-Weng Tan, Philippe L. Bédard, Jordi Rodón, Toshihiko Doi, Christian Schnell, Varsha Iyer, Fabienne Baffert, (unknown), Claire Fabre, Dejan Juric	7
12	ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy 2015 ·Blood ·Oliver G. Ottmann, Giuliana Alimena, Daniel J. DeAngelo, (unknown), Michael C. Heinrich, Andreas Hochhaus, Timothy P. Hughes, François‐Xavier Mahon, Michael J. Mauro, Hironobu Minami, (unknown), Delphine Réa, Juan Luis Steegmann, Arkendu Chatterjee, Varsha Iyer, Noelia Martínez-Jáñez, Gary Vanasse, Dong-Wook Kim	21
13	Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia 2011 ·Antimicrobial Agents and Chemotherapy ·David R. Andes, Paul G. Ambrose, Jeffrey Hammel, Scott A. Van Wart, Varsha Iyer, Daniel K. Reynolds, Donald N. Buell, Laura Kovanda, Sujata M. Bhavnani	83
14	Pharmacokinetics-Pharmacodynamics: a Primer for the Clinical Microbiologist 2011 ·Clinical Microbiology Newsletter ·Varsha Iyer, Sujata M. Bhavnani, Paul G. Ambrose	2
15	Inhibitors of phosphoinositide 3-kinase cause defects in the postendocytic sorting of β2-adrenergic receptors 2007 ·Experimental Cell Research ·Hibah O. Awwad, Varsha Iyer, (unknown), Ellen E. Millman, (unknown), Robert H. Moore, Brian J. Knoll	7
16	Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression 2006 ·Journal of Neurochemistry ·Jeffrey M. Brown, Shawn Gouty, Varsha Iyer, John Rosenberger, Brian M. Cox	33
17	Differential phosphorylation and dephosphorylation of β₂‐adrenoceptor sites Ser262 and Ser355,356 2005 ·British Journal of Pharmacology ·Varsha Iyer, Tuan M. Tran, (unknown), Wenping Dai, Richard B. Clark, Brian J. Knoll	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact